Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $27.17.

A number of research analysts recently weighed in on IMNM shares. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Monday. Lifesci Capital started coverage on Immunome in a research note on Tuesday. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Piper Sandler decreased their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMNM. Enavate Sciences GP LLC acquired a new stake in Immunome during the 4th quarter valued at $36,939,000. JPMorgan Chase & Co. boosted its position in Immunome by 2,540.4% in the 4th quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company’s stock valued at $6,888,000 after buying an additional 624,045 shares during the last quarter. Janus Henderson Group PLC boosted its position in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares during the last quarter. Granahan Investment Management LLC acquired a new stake in shares of Immunome during the fourth quarter valued at about $3,337,000. Finally, Renaissance Technologies LLC increased its position in shares of Immunome by 2,696.5% during the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company’s stock worth $3,356,000 after acquiring an additional 304,700 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Down 2.4 %

Shares of NASDAQ IMNM traded down $0.21 during trading on Tuesday, hitting $8.64. 45,067 shares of the company traded hands, compared to its average volume of 906,241. The firm has a market capitalization of $688.95 million, a P/E ratio of -1.06 and a beta of 1.93. The company has a 50-day moving average price of $10.13 and a 200-day moving average price of $11.94. Immunome has a 1 year low of $8.51 and a 1 year high of $26.70.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.